

INTEL CORP
Form 424B3
November 27, 2007

**Filed under Rule 424(b)(3) and (7) of the Securities Act of 1933,
relating to Registration No. 333-132865**

**Supplement No. 22 to Prospectus Supplement Dated March 31, 2006
and Prospectus Dated March 30, 2006**

Intel Corporation

\$1,600,000,000

2.95% Junior Subordinated Convertible Debentures due 2035

And

Shares of Common Stock Issuable Upon Conversion of the Debentures

This supplement no. 22 to the prospectus supplement dated March 31, 2006 and the prospectus dated March 30, 2006 relates to the resale by selling securityholders of Intel Corporation's 2.95% Junior Subordinated Convertible Debentures Due 2035 and the shares of Intel common stock issuable upon conversion of the debentures.

You should read this supplement no. 22 in conjunction with the prospectus supplement dated March 31, 2006, the prospectus dated March 30, 2006, and all supplements to the prospectus supplement, which should be delivered in conjunction with this supplement no. 22. This supplement no. 22 is not complete without, and may not be delivered or used except in conjunction with, the prospectus and prospectus supplement, including supplement no. 1, supplement no. 2, supplement no. 3, supplement no. 4, supplement no. 5, supplement no. 6, supplement no. 7, supplement no. 8, supplement no. 9, supplement no. 10, supplement no. 11, supplement no. 12, supplement no. 13, supplement no. 14, supplement no. 15, supplement no. 16, supplement no. 17, supplement no. 18, supplement no. 19, supplement no. 20, supplement no. 21 and any other amendments or supplements to them. This supplement no. 22 is qualified by reference to the prospectus supplement and the prospectus, except to the extent that the information provided by this supplement no. 22 supersedes information contained in the prospectus supplement, supplement no. 1, supplement no. 2, supplement no. 3, supplement no. 4, supplement no. 5, supplement no. 6, supplement no. 7, supplement no. 8, supplement no. 9, supplement no. 10, supplement no. 11, supplement no. 12, supplement no. 13, supplement no. 14, supplement no. 15, supplement no. 16, supplement no. 17, supplement 18, supplement no. 19, supplement no. 20 and supplement no. 21.

Investing in the debentures and the common stock issuable upon conversion of the debentures involves risk. See the discussion entitled Risk Factors beginning on page S-5 of the prospectus supplement dated March 31, 2006.

Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of this supplement no. 22, the prospectus supplement dated March 31, 2006 or the prospectus dated March 30, 2006. Any representation to the contrary is a criminal offense.

The table under the caption Selling Securityholders beginning on page S-54 of the prospectus supplement, as supplemented by supplement no. 1, supplement no. 2, supplement no. 3, supplement no. 4, supplement no. 5, supplement no. 6, supplement no. 7, supplement no. 8, supplement no. 9, supplement no. 10, supplement no. 11, supplement no. 12, supplement no. 13, supplement no. 14, supplement no. 15, supplement no. 16, supplement no. 17, supplement no. 18, supplement no. 19, supplement no. 20 and supplement no. 21 is hereby supplemented and amended by updating information as to certain selling securityholders identified in the table below and adding to it certain selling securityholders identified in the table below. We prepared this table based on information supplied to us by the selling securityholders named in the table below on or prior to November 27, 2007. Information about the selling securityholders may change over time. If required, any changed or new information given to us will be set forth in supplements to the prospectus supplement or amendments to the registration statement of which the prospectus, prospectus supplement and the supplements thereto, are a part, if and when necessary.

We have assumed for purposes of the table below that the selling securityholders will sell all of the debentures and all of the common stock issuable upon conversion of the debentures pursuant to this supplement no. 22, the prospectus supplement and the prospectus, and that any other shares of our common stock beneficially owned by the selling securityholders will continue to be beneficially owned.

Except as set forth below, none of the selling securityholders has, or within the past three years has had, any position, office or other material relationship with us or any of our predecessors or affiliates.

The selling securityholders identified below may have sold, transferred or otherwise disposed of, pursuant to transactions exempt from the registration requirements of the Securities Act of 1933, as amended, all or a portion of their debentures since the date on which they provided the information regarding their debentures.

Name of Selling Securityholder (1)	Principal Amount of Debentures Beneficially Owned and Offered (USD) (2)	Percentage of Debentures Outstanding (%) (3)	Number of Shares of Common Stock Issuable that May Be Sold(3)(4)	Number of Shares of Common Stock Beneficially Owned after the Offering(5)	Natural Person(s) with Voting or Investment Power (6)(7)(8)(9)(10)
RCG PB Ltd. (+)(6)	305,000	*	9,673	0	(7)
UBS Securities LLC (#)(8)	20,000	(9)	634	0	(10)

* Less than one percent (1%).

The selling securityholder is a registered broker-dealer.

+ The selling securityholder is an affiliate of a registered broker-dealer.

(1) Information concerning other selling securityholders will be set forth in additional supplements to the prospectus supplement from time to time, if required.

(2) The sum of the listed principal amounts of notes beneficially owned by the selling securityholders named in the table combined with those previously listed in the prospectus dated March 30, 2006, including supplements thereto, exceeds \$1,600,000,000 because certain selling

securityholders may have transferred notes or otherwise reduced their position prior to selling pursuant to this prospectus, and as a result we received beneficial ownership information from additional selling securityholders.

However, the maximum principal amount of notes that may be sold under this prospectus will not exceed \$1,600,000,000.

- (3) Assumes conversion of all of the holder's debentures at a conversion rate of 31.7162 shares of common stock per \$1,000 principal amount at maturity of the debentures. This conversion rate is subject to adjustment as described under

Description of debentures Conversion rights in the prospectus supplement. As a result, the number of shares of common stock issuable upon conversion of the debentures may increase or decrease in the future. Excludes shares of common stock that may be issued by us upon the repurchase of the debentures as described under

Description of debentures Fundamental change permits holders to require us to repurchase debentures and fractional shares.

Holders will receive a cash adjustment for any fractional share amount resulting from conversion of the debentures, as described under Description of debentures Conversion rights.

(4) Calculated based on Rule 13d-3(d)(i) of the Exchange Act. The number of shares of common stock beneficially owned by each holder named above is less than 1% of our outstanding common stock calculated based on 5,883 million shares of common stock outstanding as of January 27, 2006. In calculating this amount for each holder, we treated as outstanding the number of shares of common stock issuable upon conversion of all of that holder's debentures, but we did not assume conversion of any other holder's debentures.

(5) For purposes of computing the number and percentage of debentures and shares of common stock to be held by the selling securityholders after the conclusion of the offering, we have assumed for purposes of the table above that the selling securityholders named above will sell all of the debentures and

all of the common stock
issuable upon
conversion of the
debentures offered by
this prospectus, and that
any other shares of our
common stock
beneficially owned by
these selling
securityholders will
continue to be
beneficially owned.

- (6) The investment advisor to RCG PB Ltd. is Ramius Capital Group, L.L.C. An affiliate of Ramius Capital Group, L.L.C. is a NASD member. However, this affiliate will not sell any shares purchased in this offering by RCG PB Ltd. and will receive no compensation whatsoever in connection with sales of shares purchased in this transaction.
- (7) Ramius Capital Group, L.L. C. (Ramius Capital) is the investment adviser of RCG PB Ltd. (RCG PB LTD) consequently has voting control and investment discretion over securities held by RCG PB LTD. Ramius Capital disclaims beneficial ownership of the shares held by RCG PB LTD. Peter A. Cohen, Morgan

B. Stark,
Thomas W.
Strauss and
Jeffrey M.
Solomon are the
sole managing
members of
C4S & Co.,
L.L.C., the sole
managing
member of
Ramus Capital.
As a result,
Messrs. Cohen,
Stark, Strauss
and Solomon
may be
considered
beneficial
owners of any
shares deemed
to be
beneficially
owned by
Ramus Capital.
Messrs. Cohen,
Stark, Strauss
and Solomon
disclaim
beneficial
ownership of
these shares.

(8) UBS Securities
LLC was
previously listed
as holding
\$58,350,000 in
principal
amount of the
debentures. The
amount included
in this
supplement no.
22 is in addition
to the
previously listed
holdings.

(9) When
aggregated with

amounts listed
in prior
supplements,
UBS Securities
LLC would own
> 1% of
debentures
outstanding.
UBS Securities
LLC may have
sold, transferred
or otherwise
disposed of all
or a portion of
such amounts
since the date of
such prior
supplements.

- (10) UBS Securities
LLC is a
publicly held
entity.

The date of the supplement no. 22 is November 27, 2007.